MetriTrack - About the company
MetriTrack is a seed company based in Illinois City (United States), founded in 2014. It operates as an Optimal breast ultrasound technology for earlier, more accurate cancer detection. MetriTrack has raised $2.18M in funding. The company has 85 active competitors, including 37 funded and 10 that have exited. Its top competitors include companies like ScreenPoint, PreludeDx and Syantra Health.
Company Details
Optimal breast ultrasound technology for earlier, more accurate cancer detection. This medical device technology company is focused on advancing breast cancer care through automated breast ultrasound solutions. Their innovations aim to find more breast cancers faster and at a lower cost. They address the critical need for improved detection in women with dense breasts, offering a solution to overcome the limitations of traditional handheld ultrasound. Their FDA-cleared product utilizes proprietary dynamic mapping technology with anatomical referencing for precise breast volume mapping. This supports standardized, reproducible ultrasound exams, improving the quality of care throughout the breast cancer continuum, from detection to treatment. The company's mission is to save lives through earlier and more accurate detection.
Key Metrics
Founded Year
2014
Location
Illinois City, United States
Stage
Seed
Total Funding
$2.18M in 5 rounds
Latest Funding Round
Investors
Ranked
35th among 85 active competitors
Employee Count
9 as on Apr 30, 2026
Similar Companies
Legal entities associated with MetriTrack
MetriTrack is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Metritrack, Inc. CIN: 471948850 , United States, Active | Nov 05, 2014 | - | - | - |
Sign up to download MetriTrack's company profile
MetriTrack's funding and investors
MetriTrack has raised a total funding of $2.18M over 5 rounds. Its first funding round was on Feb 04, 2015. Its latest funding round was a Grant (prize money) round on Mar 01, 2019 for $*****. 1 investor participated in its latest round. MetriTrack has 1 institutional investor.
Here is the list of recent funding rounds of MetriTrack:
Filter this list
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Mar 01, 2019 | 3867587 | Grant (prize money) | 7622972 | 5400125 | 1869185 | 3764166 |
Feb 27, 2019 | 3572270 | Seed | 2074369 | 1906558 | 4231197 | 1778133 |
Oct 19, 2018 | 2897193 | Seed | 8706330 | 8002856 | 6663262 | 6680882 |
View details of MetriTrack's funding rounds and investors
MetriTrack's founders and board of directors
Founder? Claim ProfileMetriTrack's employee count trend
MetriTrack has 9 employees as of Apr 26. Here is MetriTrack's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
MetriTrack's Competitors and alternates
Top competitors of MetriTrack include ScreenPoint, PreludeDx and Syantra Health. Here is the list of Top 10 competitors of MetriTrack, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | ScreenPoint 2014, Nijmegen (Netherlands), Series C | Provider of AI-based medical image analysis systems | $47M | 63/100 | |
2nd | PreludeDx 2009, Laguna Hills (United States), Series B | Provider of risk assessment test for early stage breast cancer | $51.7M | 57/100 | |
3rd | Syantra Health 2013, Calgary (Canada), Series A | Developer of a blood test device to detect breast cancer | $10.4M | 54/100 | |
4th | Developer of PET ligands for breast cancer indications | $11.5M | 53/100 | ||
5th | Isotropic Imaging 2016, Las Vegas (United States), Public | Innovating breast cancer imaging with dedicated 3D breast CT technology | - | - | 48/100 |
6th | Devicor Medical 1959, Cincinnati (United States), Acquired | Advancing breast care through innovative diagnostic and surgical solutions | $14M | - | 48/100 |
7th | Developer of prognostic tests for the detection of cancer | $9M | 46/100 | ||
8th | Biotheranostics 2008, San Diego (United States), Acquired | Commercial stage molecular diagnostics tests tailored to individual cancer patients. | $32M | 44/100 | |
9th | Mammogen 2020, Aliso Viejo (United States), Seed | Developer of a diagnostic test to detect breast cancer | $2M | - | 44/100 |
10th | RNA Diagnostics 2010, Toronto (Canada), Series A | Developer of diagnostic assays for the detection of cancer | $13.8M | 41/100 | |
35th | MetriTrack 2014, Illinois City (United States), Seed | Optimal breast ultrasound technology for earlier, more accurate cancer detection | $2.18M | 31/100 |
Looking for more details on MetriTrack's competitors? Click here to see the top ones
MetriTrack's Investments and acquisitions
MetriTrack has made no investments or acquisitions yet.
News related to MetriTrack
•
•
•
Are you a Founder ?
FAQs about MetriTrack
Explore our recently published companies
- Moatindia - 2012 founded, Unfunded company
- Schoeler Kreativ - Immenstadt based, Unfunded company
- Aecs Pune - 2010 founded, Unfunded company
- Microestimating - San Francisco based, 2004 founded, Unfunded company
- Constructionphotographers - Burlingame based, Unfunded company
- N M Stones - India based, Unfunded company